share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director ADAMIS ANTHONY P

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director ADAMIS ANTHONY P

EyePoint Pharmaceuticals | 4:持股變動聲明-董事 ADAMIS ANTHONY P
美股SEC公告 ·  06/25 16:23
Moomoo AI 已提取核心訊息
Anthony P. Adamis, associated with EyePoint Pharmaceuticals, Inc. [EYPT], completed a transaction on June 23, 2024, acquiring 2,000 shares of common stock at no cost. This transaction was categorized as an exercise or conversion of derivative security, conducted directly by Adamis. Following this acquisition, Adamis's direct holdings in EyePoint Pharmaceuticals increased to a total of 4,000 shares of common stock.
Anthony P. Adamis, associated with EyePoint Pharmaceuticals, Inc. [EYPT], completed a transaction on June 23, 2024, acquiring 2,000 shares of common stock at no cost. This transaction was categorized as an exercise or conversion of derivative security, conducted directly by Adamis. Following this acquisition, Adamis's direct holdings in EyePoint Pharmaceuticals increased to a total of 4,000 shares of common stock.
與eyepoint pharmaceuticals有關的Anthony P. Adamis於2024年6月23日完成了一筆交易,免費獲得了2000股普通股。此次交易被歸類爲衍生證券的行權或轉換,由Adamis直接進行。在此次收購後,Adamis在eyepoint pharmaceuticals的直接持股增至總共4000股普通股。
與eyepoint pharmaceuticals有關的Anthony P. Adamis於2024年6月23日完成了一筆交易,免費獲得了2000股普通股。此次交易被歸類爲衍生證券的行權或轉換,由Adamis直接進行。在此次收購後,Adamis在eyepoint pharmaceuticals的直接持股增至總共4000股普通股。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息